<https://rdf.molmedb.upol.cz/reference/ref3533> <http://purl.org/ontology/bibo/pmid> "32551004"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://rdf.molmedb.upol.cz/interaction/method33>;
	<http://purl.org/ontology/bibo/doi> "10.1021/acsmedchemlett.0c00063"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/dc/terms/BibliographicResource>;
	<http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM490936>;
	<http://purl.org/dc/terms/bibliographicCitation> "Cherney RJ, Cornelius LAM, Srivastava A, Weigelt CA, Marcoux D, Duan JJ, Shi Q, Batt DG, Liu Q, Yip S, Wu DR, Ruzanov M, Sack J, Khan J, Wang J, Yarde M, Cvijic ME, Mathur A, Li S, Shuster D, Khandelwal P, Borowski V, Xie J, Obermeier M, Fura A, Stefanski K, Cornelius G, Tino JA, Macor JE, Salter-Cid L, Denton R, Zhao Q, Carter PH, Dhar TGM.: Discovery of BMS-986251: A Clinically Viable, Potent, and Selective RORγt Inverse Agonist. ACS Med Chem Lett, Volume 11 (6), 2020"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://rdf.molmedb.upol.cz/interaction/membrane21> .
<https://rdf.molmedb.upol.cz/interaction/int1024769> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3533> .